The Pharmacy Times® Pain Management Resource Center is a comprehensive resource for clinical news and expert insights on managing chronic pain with prescription drugs, OTC medications, and physical therapy.
January 31st 2025
Although there were increases in prescriptions during the studies’ durations, the proportion of anxiety or pain medications on the same day of intrauterine device (IUD) insertion procedures were low.
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
1.5 Credits / Cardiology, Neurology, Rare Diseases
View More
Navigating Parkinson Disease: Innovative Approaches to Mitigate OFF Episodes
1.0 Credit / Neurology
View More
The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of ...
1.0 Credit / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements
2.0 Credits / Psychiatry
View More
Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia
3.0 Credits / Psychiatry
View More
Collaborating Across the Continuum™: Identifying and Preventing Hepatic Encephalopathy in Long-Term Care Setti...
1.25 Credits / Neurology
View More
Addressing the Unmet Needs in the Management of Myasthenia Gravis: The Role of New and Emerging Therapies
1.5 Credits / Neurology
View More
In-Depth Insights and Application in the Management of Immunoglobulin Therapy
1.0 Credit / Neurology, Immunology
View More
Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies
1.0 Credit / Psychiatry
View More
Revolutionizing Acute Pain Relief: Emerging Non-Opioid Therapies and the Essential Role of Pharmacists
1.5 Credit / Pain Management/Opioids
View More
Overview and Burden of Migraine
0.5 Credit / Neurology
View More
The Evolving Treatment Landscape of Migraine
0.5 Credit / Neurology
View More
The Role of the Pharmacist Migraine Management
0.5 Credit / Neurology
View More
Combating Opioid Overdoses: The Impact of Pharmacist-led Counseling and Dispensing of Opioid Reversal Agents
1.0 Credit / Pain Management/Opioids
View More
FDA Panel Recommends Abuse-Deterrent Oxycodone Tablets
November 16th 2018The Committees voted 12 to 5 that the drug should be labeled as an abuse-deterrent product by the nasal route of abuse, but they voted 10 to 7 that the drug should not be labeled as an abuse-deterrent product by the intravenous route of abuse.
Read More
Pharmaceutical Industry Giving Attention to Cannabis 'Cousin'
August 1st 2018Ned Milenkovich, PharmD, JD, is chairman of the health care law practice at Much Shelist PC in Chicago, and former vice chairman of the Illinois State Board of Pharmacy. In this video, he discusses hemp, and why it is drawing increased attention from the pharmacuetical industry.
Watch
Elimination of Long-Term Opioid Therapy Found to Stabilize or Reduce Chronic PainÂ
July 16th 2018The discontinuation of opioid therapy may address the rising death toll caused by drug overdoses while maintaining or potentially improving chronic, non-cancer pain in patients, according to a recent study.
Read More
FDA Advisory Committee Recommends Against Approving Abuse-Deterrent Pain Med
June 28th 2018The FDA voted against recommendign oxycodone extended-release capsules (REMOXY ER, Pain Therapeutics) for approval for the management of pain severe enough to require long-term, around-the-clock opioid treatment, during a joint meeting of the agency’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC), and the Drug Safety and Risk Management Advisory Committee (DSARM).
Read More